Tesamorelin

Tesamorelin

$89.99

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH 1-44), developed to enhance the natural secretion of growth hormone (GH). Unlike shorter-acting peptides, Tesamorelin has been FDA-approved (under the brand name Egrifta®) for reducing visceral adipose tissue (VAT) in HIV-associated lipodystrophy. Its ability to stimulate endogenous GH release makes it a powerful research peptide for exploring fat metabolism, lean body mass enhancement, and endocrine aging.
Tesamorelin is valued for its targeted fat-reducing effects, particularly around abdominal organs, without the risks associated with exogenous GH administration.

Benefits:

• Reduces Visceral Fat: Clinically proven to reduce VAT, especially in lipodystrophic conditions.
• Stimulates Endogenous GH: Promotes natural pulsatile release of GH, leading to increased IGF-1 levels.
• Improves Metabolic Profile: Shown to improve triglyceride levels and insulin sensitivity in some studies.
• Preserves Lean Muscle Mass: Encourages an increase in lean tissue and supports protein synthesis.
• FDA-Approved Indication: Used in clinical settings for HIV-associated fat redistribution.
• No Direct GH Administration: Lowers the risk of GH overdose and desensitization by using the body’s own pathways.

Category:

Description

Clinical Evidence

• A 2010 study published in the New England Journal of Medicine demonstrated that Tesamorelin significantly reduced visceral fat in HIV-infected patients with lipodystrophy.
• Follow-up trials showed improvements in IGF-1 levels, body composition, and cardiometabolic markers.
• Unlike direct GH therapy, Tesamorelin maintains normal feedback regulation, reducing the risk of long-term hormone suppression.
Tesamorelin has a half-life of approximately 20–30 minutes but exerts prolonged biological activity through GHRH receptor stimulation.

 

Potential Side Effects

Tesamorelin is generally well tolerated in clinical trials. Possible side effects include:
• Redness or swelling at injection site
• Mild joint pain or muscle soreness
• Increased blood sugar levels (monitoring advised in metabolic studies)
• Headache or tingling sensations
• Rare: hypersensitivity reactions or localized swelling
While side effects are typically mild, studies recommend monitoring IGF-1 levels and glucose metabolism during extended use.

 

Disclaimer

This peptide is intended for research use only and is not approved for non-clinical human or veterinary use outside of FDA-labeled indications. All references to clinical benefits are based on published research and regulated medical use. It must be handled by professionals in a licensed laboratory or research setting.

Additional information

MG

10

Reviews

There are no reviews yet.

Be the first to review “Tesamorelin”

Related products

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping